EDDING GENOR (06998) enters into a supplemental agreement and termination agreement with Napeptide.

EDDING GENOR (06998) announces that on March 3, 2026, the Group entered into a supplementary agreement and termination agreement (referred to as the "Agreements") with Naspeptides (Qingdao) Biopharmaceutical Co., Ltd. (Naspeptides). The Agreements relate to the authorization and introduction arrangements entered into by the Group and Naspeptides regarding several siRNA assets. In September 2023, the Group and Naspeptides entered into an authorization and introduction agreement to obtain exclusive development, production, and commercialization rights for two innovative preclinical siRNA assets, and in May 2024 further authorized the introduction of another siRNA asset. According to the Agreements, the parties agreed to make the following adjustments to the cooperation arrangements: (i) the territorial scope of one siRNA asset (i.e., angiopoietin-like protein 3 (ANGPTL3) has been expanded from the originally agreed territory to global, allowing the Group to obtain global patent rights related to the ANGPTL3 molecule and jointly own the GalNAc platform technology with Naspeptides; and (ii) the cooperation arrangements for the other two preclinical siRNA assets have been terminated. Following the signing of the supplementary agreement, the licensing territory for the siRNA asset ANGPTL3 has been expanded to a global scope, further enhancing its asset value within the company, and benefiting the long-term shareholder value of the company. The company's candidate drug EDP167 for ANGPTL3 has successfully completed dosing in its Phase II clinical trial. Considering the market competitive environment, the company has terminated the cooperation arrangements for the other two preclinical siRNA assets. As the other two siRNA assets are still in the early stages of research and development, the termination of cooperation with regard to these assets will not have any significant adverse impact on the Group's business, financial condition, or operations.